Gene that drives blood cancer drug resistance uncovered with new CRISPR activation tool

Experiments showed that when this gene was silenced, cancer cells regained their responsiveness to treatment

Researchers at the Olivia Newton-John Cancer Research Institute have identified a previously unknown gene that causes resistance to a leading blood cancer treatment. The discovery was made using a novel CRISPR activation tool designed to systematically screen for genes involved in drug resistance. This breakthrough could help explain why some patients stop responding to therapy over time and may guide the development of more effective treatments. The research focused on acute myeloid leukemia, a type of blood cancer where resistance to targeted therapies remains a major challenge. By activating genes across the genome with the new CRISPR tool, scientists were able to pinpoint a specific gene whose increased activity directly correlated with reduced drug sensitivity.

Experiments showed that when this gene was silenced, cancer cells regained their responsiveness to treatment, confirming its role in driving resistance. How the CRISPR Activation Tool Revealed Hidden Resistance Mechanisms Unlike traditional CRISPR methods that knock out genes, this approach activates gene expression to uncover factors that promote resistance when overactive. The tool allowed researchers to test thousands of genes in parallel, identifying the novel gene as a key player in bypassing the effects of standard inhibitors. Follow-up experiments in cell models and patient-derived samples validated the finding, showing consistent association between gene expression levels and treatment failure. Could Targeting This Gene Improve Existing Therapies? Scientists are now exploring whether inhibiting this gene could restore sensitivity to current drugs, potentially extending the effectiveness of treatment for patients who relapse. Early data suggest combining standard therapy with a blocker against this gene may overcome resistance in laboratory models.

The team emphasizes that further validation in clinical settings is needed, but the target appears promising due to its specific role in resistance mechanisms rather than general cell survival. Frequently Asked Questions What type of cancer was studied in this research? The study focused on acute myeloid leukemia, a fast-growing blood cancer that often develops resistance to targeted therapies over time. How does the new CRISPR tool differ from standard gene editing? Instead of cutting or disabling genes, this CRISPR activation method turns genes on to identify those that, when overactive, cause treatment resistance. Is this gene already known to be involved in cancer? No, the gene was previously unidentified and not linked to drug resistance in blood cancers before this discovery.